// App-Quantinova.ai

3031 : Proof of mechanism (POM) in the first-in-human trial of two novel indenoisoquinoline, non-camptothecin topoisomerase I (TOP1) inhibitors.

Researchers

Presenter

  • James H. Doroshow

Principal Investigators

  • Alice Chen

  • Marcie K. Weil

  • Julie Eiseman

  • Julianne L. Holleran

  • Robert J. Kinders

  • Jan Hendrik Beumer

  • Ralph E. Parchment

  • Yves Pommier

  • Joseph E. Tomaszewski

  • Shivaani Kummar

  • Deborah Allen

  • Yiping Zhang

  • Scott M Lawrence

  • Thomas D. Pfister

  • Lihua Wang

  • Christophe E. Redon

  • William Bonner

  • Giovanna Speranza

Medical Centers

  • NCI NIH Division of Cancer Treatment and Diagnosis, Bethesda, MD

  • Division of Cancer Treatment and Diagnosis, Natl Cancer Inst, Bethesda, MD

  • University of Pittsburgh Cancer Institute, Pittsburgh, PA

  • NCI, Rockville, MD

  • SAIC-Frederick, Bethesda, MD

  • University of Pittsburgh, Pittsburgh, PA

  • National Cancer Institute, Bethesda, MD

  • SAIC-Frederick, Frederick, MD

  • National Cancer Institute, Rockville, MD

  • University of Pittsburgh Medical Center, Pittsburgh, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Refractory malignancies

Biomarkers

  • Circulating tumor cells

  • Topoisomerase-1

Drug/Treatment

  • camptothecin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved